Medical Center Asclepius Ltd.
- Address
- Ulitsa Iskra 15, 4600 Velingrad, Bulgaria
Cardiovascular Disease Research Center
Medical Center Asclepius Ltd. specializes in advanced cardiovascular research, with particular emphasis on atherosclerotic cardiovascular disease (ASCVD) management. The center focuses on evaluating novel therapeutic approaches for patients whose current lipid-modifying treatments are insufficient in controlling their cardiovascular risk.
- Phase 3 clinical trials for innovative cholesterol-lowering therapies
- Major adverse cardiovascular events (MACE) prevention strategies
- Advanced lipid-modifying treatment protocols for high-risk ASCVD patients
The research center is actively engaged in studying obicetrapib, a promising agent for reducing cardiovascular events including CV death, non-fatal myocardial infarction, non-fatal stroke, and coronary revascularization procedures. This work addresses the critical need for improved treatment options in patients with atherosclerotic disease characterized by arterial narrowing due to plaque buildup.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Merck Sharp & Dohme LLC1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Center Asclepius Ltd.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Molnupiravir in Non-Hospitalized Adults with SARS-CoV-2 Infection at High Risk for Disease Progression | Merck Sharp & Dohme LLC | Phase III | Recruiting | Feb 2025 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| MOLNUPIRAVIR | 1 | Unknown | 2025-02-21 | 2025-02-21 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.